Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.

NCT01902680 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT01902680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01902680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.
Lead sponsor
Institut Claudius Regaud
Phase
Phase 2
Overall status
Completed
Start date
August 23, 2013
Completion date
June 6, 2017
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

localized prostate cancer